血管性帕金森综合征鉴别诊断的影像学研究进展

doi:10.3969/j.issn.1673－5765.2023.08.003

摘要/Abstract

摘要： 血管性帕金森综合征（vascular parkinsonism，VP）是临床上常见的继发性帕金森综合征，目前VP临床诊断和鉴别诊断的准确率较低，影响其临床治疗和预后。在临床实践中，影像学常用于VP的诊断。近年来多模态MRI和分子影像成像及分析技术等影像学技术的进展为提高VP的诊断和鉴别诊断准确率提供了客观手段。本文就前沿影像学技术在VP与原发性帕金森病以及其他非典型帕金森综合征鉴别诊断领域的研究进展进行综述，以期为VP的诊断和鉴别诊断提供新的思路。

文章导读： 本文就多模态MRI、分子影像成像及分析技术等前沿影像学技术进行了总结，对该领域的探索有助于血管性帕金森综合征的诊断与鉴别诊断。

关键词: 血管性帕金森综合征; 高分辨结构像; 弥散张量成像; 磁敏感加权成像; 神经黑色素敏感成像; 分子影像

Abstract: Vascular parkinsonism is a common secondary parkinsonism. At present, the accuracy of diagnosis and differential diagnosis of vascular parkinsonism is low, which affects its treatment and prognosis. Imaging is commonly used in clinical practice to diagnose vascular parkinsonism. In recent years, the advance of multimodal MRI and molecular imaging and analysis technology has provided objective methods to improve the accuracy of diagnosis and differential diagnosis of vascular parkinsonism. This paper reviews the latest progress of various cutting-edge imaging techniques in the differential diagnosis of vascular parkinsonism from idiopathic Parkinson’s disease and other atypical parkinsonisms, hoping to provide new ideas for the diagnosis and differential diagnosis of vascular parkinsonism.

Key words: Vascular parkinsonism; High-resolution structural imaging; Diffusion tensor imaging; Susceptibility weighted imaging; Neuromelanin sensitive magnetic resonance imaging; Molecular imaging

张冬玲, 吴涛. 血管性帕金森综合征鉴别诊断的影像学研究进展[J]. 中国卒中杂志, 2023, 18(8): 867-872.

ZHANG Dongling, WU Tao. Advances of Imaging in the Differential Diagnosis of Vascular Parkinsonism[J]. Chinese Journal of Stroke, 2023, 18(8): 867-872.

参考文献

[1] 中华医学会神经病学分会帕金森病及运动障碍学组，中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会. 中国血管性帕金森综合征诊断与治疗专家共识[J]. 中华神经科杂志，2017，50（5）：326-331.
Parkinson’s Disease & Movement Disorders Society，Chinese Society of Neurology，Parkinson’s Disease & Movement Disorders Society，Chinese Neurology Association. Chinese experts’consensus of diagnosis and treatment of vascular parkinsonism[J]. Chin J Neurol，2017，50（5）：326-331.
[2] VALE T C，CARAMELLI P，CARDOSO F. Clinicoradiological comparison between vascular parkinsonism and Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry，2015，86（5）：547-553.
[3] KORCZYN A D. Vascular parkinsonism--characteristics，pathogenesis and treatment[J]. Nat Rev Neurol，2015，11（6）：319-326.
[4] KALRA S，GROSSET D G，BENAMER H T. Differentiating vascular parkinsonism from idiopathic Parkinson’s disease：a systematic review[J]. Mov Disord，2010，25（2）：149-156.
[5] SCHUEPBACH W M，RAU J，KNUDSEN K，et al. Neurostimulation for Parkinson’s disease with early motor complications[J]. N Engl J Med，2013，368（7）：610-622.
[6] SHIH L C，TARSY D. Deep brain stimulation for the treatment of atypical parkinsonism[J]. Mov Disord，2007，22（15）：2149-2155.
[7] SHIN H W，HONG S W，YOUN Y C. Clinical aspects of the differential diagnosis of Parkinson’s disease and parkinsonism[J]. J Clin Neurol，2022，18（3）：259-270.
[8] RACCAGNI C，NONNEKES J，BLOEM B R，et al. Gait and postural disorders in parkinsonism：a clinical approach[J]. J Neurol，2020，267（11）：3169-3176.
[9] NARASIMHAN M，SCHWARTZ R，HALLIDAY G. Parkinsonism and cerebrovascular disease[J/OL]. J Neurol Sci，2022，433：120011[2023-02-15]. https://doi.org/10.1016/j.jns.2021.120011.
[10] KALRA S，GROSSET D G，BENAMER H T. Differentiating vascular parkinsonism from idiopathic Parkinson’s disease：a systematic review[J]. Mov Disord，2010，25（2）：149-156.
[11] VALE T C，CARAMELLI P，CARDOSO F. Clinicoradiological comparison between vascular parkinsonism and Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry，2015，86：547-553.
[12] KIM J S. Involuntary movements after anterior cerebral artery territory infarction[J]. Stroke，2001，32（1）：258-261.
[13] ZIJLMANS J C. The role of imaging in the diagnosis of vascular parkinsonism[J]. Neuroimaging Clin N Am，2010，20（1）：69-76.
[14] BOHNEN N I，ALBIN R L. White matter lesions in Parkinson disease[J]. Nat Rev Neurol，2011，7（4）：229-236.
[15] DE OLIVEIRA P，MARTINS B J，CARDOSO F E C. White matter hyperintensity presence，quantity，and location exhibits no association with motor and non-motor manifestations of PD[J/OL]. Parkinsonism Relat Disord，2023，106：105245[2023-02-10]. https://doi.org/10.1016/j.parkreldis.2022.105245.
[16] MA K K Y，LIN S，MOK V C T. Neuroimaging in vascular parkinsonism[J/OL]. Curr Neurol Neurosci Rep，2019，19（12）：102[2023-02-11]. https://doi.org/10.1007/s11910-019-1019-7.
[17] DUNET V，DEVERDUN J，CHARROUD C，et al. MRI volumetric morphometry in vascular parkinsonism[J]. J Neurol，2017，264（7）：1511-1519.
[18] CHOI S M，KIM B C，NAM T S，et al. Midbrain atrophy in vascular parkinsonism[J]. Eur Neurol，2011，65（5）：296-301.
[19] MOSTILE G，NICOLETTI A，CICERO C E，et al. Magnetic resonance parkinsonism index in progressive supranuclear palsy and vascular parkinsonism[J]. Neurol Sci，2016，37（4）：591-595.
[20] QUATTRONE A，BIANCO M G，ANTONINI A，et al. Development and validation of automated magnetic resonance parkinsonism index 2.0 to distinguish progressive supranuclear palsy-parkinsonism from Parkinson’s disease[J]. Mov Disord，2022，37（6）：1272-1281.
[21] KIM B C，CHOI S M，CHOI K H，et al. MRI measurements of brainstem structures in patients with vascular parkinsonism，progressive supranuclear palsy，and Parkinson’s disease[J]. Neurol Sci，2017，38（4）：627-633.
[22] BENVENISTE H，ELKIN R，HEERDT P M，et al. The glymphatic system and its role in cerebral homeostasis[J]. J Appl Physiol，2020，129（6）：1330-1340.
[23] TROILI F，CIPOLLINI V，MOCI M，et al. Perivascular Unit：this must be the place. The anatomical crossroad between the immune，vascular and nervous system[J/OL]. Front Neuroanat，2020，14：17[2023-02-10]. https://doi.org/10.3389/fnana.2020.00017.
[24] TU Y，ZHUO W Y，PENG J W，et al. The correlation between enlarged perivascular spaces and cognitive impairment in Parkinson’s disease and vascular parkinsonism[J]. BMC Neurol，2022，22（1）：282.
[25] WANG H C，HSU J L，LEEMANS A. Diffusion tensor imaging of vascular parkinsonism：structural changes in cerebral white matter and the association with clinical severity[J]. Arch Neurol，2012，69（10）：1340-1348.
[26] MANIEGA S M，VALDÉS HERNÁNDEZ M C，CLAYDEN J D，et al. White matter hyperintensities and normal appearing white matter integrity in the aging brain[J]. Neurobiol Aging，2015，36（2）：909-918.
[27] SALSONE M，CALIGIURI M E，VESCIO V，et al. Microstructural changes of normal-appearing white matter in vascular parkinsonism[J/OL]. Parkinsonism Relat Disord，2019，63：60-65[2023-02-10]. https://doi.org/10.1016/j.parkreldis.2019.02.046.
[28] WISE R M，WAGENER A，FIETZEK U M，et al. Interactions of dopamine，iron，and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson’s disease and neurodegeneration with brain iron accumulation disorders[J/OL]. Neurobiol Dis，2022，175：105920[2023-02-10]. https://doi.org/10.1016/j.nbd.2022.105920.
[29] HALLER S，HAACKE E M，THURNHER M M，et al. Susceptibility-weighted Imaging：technical essentials and clinical neurologic applications[J]. Radiology，2021，299（1）：3-26.
[30] BAE Y J，KIM J M，KIM E，et al. Loss of nigral hyperintensity on 3 tesla MRI of parkinsonism：comparison with 123I-FP-CIT SPECT[J]. Mov Disord，2016，31（5）：684-692.
[31] ZHAO X J，NIU X Y，YOU H Y，et al. Signal alteration of substantia nigra on 3. 0T susceptibility-weighted imaging in Parkinson’s Disease and vascular parkinsonism[J]. Curr Med Sci，2019，39（5）：831-835.
[32] MARTIN-BASTIDA A，PIETRACUPA S，PICCINI P. Neuromelanin in parkinsonian disorders：an update[J]. Int J Neurosci，2017，127（12）：1116-1123.
[33] HE N Y，CHEN Y S，LEWITT P A，ET AL. Application of neuromelanin MR imaging in Parkinson Disease[J]. J Magn Reson Imaging，2023，57（2）：337-352.
[34] NOBILEAU A，GAURAV R，CHOUGAR L，et al. Neuromelanin-sensitive magnetic resonance imaging changes in the locus coeruleus/subcoeruleus complex in patients with typical and atypical Parkinsonism[J]. Mov Disord，2023，38（3）：479-484.
[35] WANG E W，BROWN G L，LEWIS M M，et al. Susceptibility magnetic resonance imaging correlates with glial density and tau in the substantia nigra pars compacta[J]. Mov Disord，2023，38（3）：464-473.
[36] MATSUURA K，II Y，MAEDA M，et al. Neuromelanin-sensitive magnetic resonance imaging in disease differentiation for parkinsonism or neurodegenerative disease affecting the basal ganglia[J/OL]. Parkinsonism Relat Disord，2021，87：75-81[2023-02-01]. https://doi.org/10.1016/j.parkreldis.2021.05.002.
[37] GOLAN H，VOLKOV O，SHALOM E. Nuclear imaging in Parkinson’s disease：the past，the present，and the future[J/OL]. J Neurol Sci，2022，436：120220[2023-02-15]. https://doi.org/10.1016/j.jns.2022.120220.
[38] WALLERT E D，VAN DE GIESSEN E，KNOL R J J，et al. Imaging dopaminergic neurotransmission in neurodegenerative disorders[J]. J Nucl Med，2022，63（Suppl 1）：27S-32S.
[39] PARK D G，KANG S Y，HONG J Y，et al. Factors associated with motor severity in vascular parkinsonism with normal dopamine transporter imaging[J]. Parkinsonism Relat Disord，2022，94：99-103.
[40] BENITEZ-RIVERO S，MARÍN-OYAGA V A，GARCÍA-SOLÍS D，et al. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry，2013，84（2）：122-129.
[41] SOLLA P，CANNAS A，ARCA R，et al. Focal 123I-FP-CIT SPECT abnormality in midbrain vascular parkinsonism[J/OL]. Case Rep Neurol Med，2015，2015：642764[2023-02-15]. https://doi.org/10.1155/2015/642764.
[42] ZIJLMANS J，EVANS A，FONTES F，et al. 123I FP-CIT spect study in vascular parkinsonism and Parkinson’s disease[J]. Mov Disord，2007，22（9）：1278-1285.
[43] BOOTH T C，NATHAN M，WALDMAN A D，et al. The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes，part 1[J]. AJNR Am J Neuroradiol，2015，36：229-235.